Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of
deaths and substantial morbidity worldwide. Intense scientific effort to understand the …

The COVID-19 pandemic has been met with an unprecedented response from the scientific
community, leading to the development, investigation, and authorization of vaccines and …

The nucleoside analog β-DN 4-hydroxycytidine is the active metabolite of the prodrug
molnupiravir and is accepted as an efficient drug against COVID-19. Molnupiravir targets the …

Some medically important viruses―including retroviruses, flaviviruses, coronaviruses, and
herpesviruses―code for a protease, which is indispensable for viral maturation and …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was the seventh
known human coronavirus, and it was identified in Wuhan, Hubei province, China, in 2020. It …

Immunocompromised patients still experience unpredictable courses of COVID-19, despite
that effective vaccines and drugs against SARS-CoV-2 are now available. Antiviral …

The periodic emergence of SARS-CoV-2 variants of concern (VOCs) with unpredictable
clinical severity and ability to escape preexisting immunity emphasizes the continued need …

Background: This study aims to investigate the activity of the remdesivir–nirmatrelvir
combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and …

Summary N4-hydroxycytidine (NHC), the active compound of the drug Molnupiravir, is
incorporated into SARS-CoV-2 RNA, causing false base pairing. The desired result is an" …

Abstract Molnupiravir (EIDD-2801) is a prodrug of a ribonucleoside analogue that is
currently being used under a US FDA emergency use authorization for the treatment of mild …